What is your preferred first line approach to patients with Stage IV non-squamous NSCLC with good performance status, no driver mutations, PD-L1 low-positive, and CKD IIIB or worse, CrCl < 45 mL/min?
Assuming the patient had no contraindications to immunotherapy and no other significant comorbidities.
Answer from: Medical Oncologist at Community Practice
This is a common scenario. For patients with PD-L1 high tumors, would certainly, of course, feel comfortable with ICI monotherapy. For squamous NSCLC with PD-L1 low or negative, the question is more straightforward since taxane can be given in the setting of renal insufficiency. For nonsquamous NSCL...
Sign in or Register to read more